We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

AC Immune SA (ACIU) CHF0.02

Sell:$2.69 Buy:$2.71 Change: $0.01 (0.37%)
NASDAQ:0.14%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$2.69
Buy:$2.71
Change: $0.01 (0.37%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$2.69
Buy:$2.71
Change: $0.01 (0.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Contact details

Address:
EPFL Innovation Park, Building B
LAUSANNE
1015
Switzerland
Telephone:
+41 (21) 3459121
Website:
https://www.acimmune.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ACIU
ISIN:
CH0329023102
Market cap:
$264.63 million
Shares in issue:
99.20 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Switzerland
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Andrea Pfeifer
    Chief Executive Officer, Co-Founder, Director
  • Christopher Roberts
    Chief Financial Officer, Vice President - Finance
  • Piergiorgio Donati
    Chief Technical Operations Officer
  • Howard Donovan
    Chief Human Resource Officer
  • Jean-Fabien Monin
    Chief Administrative Officer
  • Madiha Derouazi
    Chief Scientific Officer
  • Nuno Mendonca
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.